Related Experiment Videos

[Psychopharmacological treatment of patients complicated with cardiovascular disease]

Tetsuaki Inamitsu1

  • 1Section of Palliative Care and Psychosomatic Medicine, Oikawa Hospital.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|March 15, 2012
PubMed

Insights

Psychiatric conditions like depression and anxiety worsen cardiovascular disease prognosis. Careful consideration of drug interactions and psychological support is crucial for managing these patients.

Area of Science:

  • Cardiology
  • Psychiatry
  • Pharmacology

Context:

  • Cardiovascular diseases (CVD) frequently co-occur with psychiatric conditions.
  • Psychological factors significantly impact CVD prevalence and prognosis.
  • Managing these comorbid conditions requires a multidisciplinary approach.

Purpose:

  • To highlight the intricate relationship between psychiatric disorders and cardiovascular diseases.
  • To outline key pharmacological considerations in treating patients with comorbid CVD and psychiatric issues.
  • To emphasize the importance of integrated psychological interventions in cardiac care.

Summary:

  • Depression and anxiety are linked to increased CVD prevalence and poorer outcomes.
  • Potential drug interactions between psychotropic and cardiovascular medications, including effects on hypotension, QT prolongation, and cytochrome P450 activity, must be managed.
  • Psychological approaches and therapeutic relationships are vital components of cardiac rehabilitation.

Impact:

  • Improved patient outcomes through comprehensive management of comorbid psychiatric and cardiovascular conditions.
  • Enhanced understanding of drug-drug interactions for safer psychopharmacological and cardiovascular prescribing.
  • Integration of psychological care into cardiac rehabilitation settings for holistic patient recovery.

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...